Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (2) Autor Figueiredo,G.L. (2) Lima-Filho,M.O. (2) Marin-Neto,J.A. (2) Antloga,C.M. (1) Badran,A.V. (1) Foss,M.C. (1) Foss-Freitas,M.C. (1) Lago,I.M. (1) Lemos,D.C. (1) Lorenzi,J.C. (1) Marchini,J.F.M. (1) Novaes,G.C. (1) Oliveira,L. (1) Pavão,R.B. (1) Pinto,M.R. (1) Tonani,M. (1) Mais... Palavra-chave Aspirin (1) Clopidogrel (1) Coronary restenosis (1) Coronary stents (1) Diabetes mellitus (1) Dysglycemia (1) Insulin resistance (1) Percutaneous coronary intervention (1) Platelet function tests (1) Single nucleotide polymorphism (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2017 (1) 2010 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients BJMBR Marchini,J.F.M.; Pinto,M.R.; Novaes,G.C.; Badran,A.V.; Pavão,R.B.; Figueiredo,G.L.; Lago,I.M.; Lima-Filho,M.O.; Lemos,D.C.; Tonani,M.; Antloga,C.M.; Oliveira,L.; Lorenzi,J.C.; Marin-Neto,J.A.. Clopidogrel and aspirin are the most commonly used medications worldwide for dual antiplatelet therapy after percutaneous coronary intervention. However, clopidogrel hyporesponsiveness related to gene polymorphisms is a concern. Populations with higher degrees of genetic admixture may have increased prevalence of clopidogrel hyporesponsiveness. To assess this, we genotyped CYP2C19, ABCB1, and PON1 in 187 patients who underwent percutaneous coronary intervention. Race was self-defined by patients. We also performed light transmission aggregometry with adenosine diphosphate (ADP) and arachidonic acid during dual antiplatelet therapy. We found a significant difference for presence of the CYP2C19*2 polymorphism between white and non-white patients. Although 7%... Tipo: Info:eu-repo/semantics/article Palavras-chave: Platelet function tests; Single nucleotide polymorphism; Percutaneous coronary intervention; Aspirin; Clopidogrel. Ano: 2017 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000100702 Predictors of restenosis after percutaneous coronary intervention using bare-metal stents: a comparison between patients with and without dysglycemia BJMBR Lima-Filho,M.O.; Figueiredo,G.L.; Foss-Freitas,M.C.; Foss,M.C.; Marin-Neto,J.A.. The objective of this study was to identify intravascular ultrasound (IVUS), angiographic and metabolic parameters related to restenosis in patients with dysglycemia. Seventy consecutive patients (77 lesions) selected according to inclusion and exclusion criteria were evaluated by the oral glucose tolerance test and the determination of insulinemia after a successful percutaneous coronary intervention (PCI) with a bare-metal stent. The degree of insulin resistance was calculated by the homeostasis model assessment of insulin resistance (HOMA-IR). Six-month IVUS and angiogram follow-up were performed. Thirty-nine patients (55.7%) had dysglycemia. The restenosis rate in the dysglycemic group was 37.2 vs 23.5% in the euglycemic group (P = 0.299). The... Tipo: Info:eu-repo/semantics/article Palavras-chave: Coronary stents; Coronary restenosis; Insulin resistance; Diabetes mellitus; Dysglycemia. Ano: 2010 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010000600008 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco